File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma

TitleEffectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma
Authors
KeywordsAdolescent
Adult
Aged
Aged, 80 and over
Brachytherapy/*methods
Carcinoma/mortality/pathology/radiotherapy
Cohort Studies
Combined Modality Therapy
Dose Fractionation
Dose-Response Relationship, Radiation
Female
Follow-Up Studies
Humans
Immunohistochemistry
Male
Middle Aged
Nasopharyngeal Neoplasms/mortality/pathology/*radiotherapy
Neoplasm Recurrence, Local/mortality/pathology/*radiotherapy/*surgery
Neoplasm Staging
Radiosurgery/*methods
Radiotherapy Dosage
Retrospective Studies
Risk Assessment
*Salvage Therapy
Survival Analysis
Treatment Outcome
Issue Date2004
Citation
Head Neck, 2004, v. 26 n. 12, p. 1024-1030 How to Cite?
AbstractBACKGROUND: Nasopharyngeal carcinoma (NPC) with local persistence after primary radiotherapy carries a high risk of treatment failure. We compared the effectiveness of brachytherapy and a fractionated stereotactic radiotherapy (SRT) boost in improving tumor control. METHODS: We retrospectively reviewed the records of 755 patients with NPC treated from 1994 to 2001. Fifty-two patients (7%) had persistent local disease, but seven of them were unsuitable for radiotherapy boost. Overall, 24 patients received brachytherapy boost at a median dose of 20 Gy, and 21 patients received an SRT boost at a median dose of 15 Gy. RESULTS: Despite the radiotherapy boost, the overall 3-year local failure-free control rate was still significantly lower for patients with persistent disease than for the rest (71% vs 86%, p < .01). Only the SRT subgroup achieved a local failure-free control rate close to that of the complete responders (82% vs 86%, p = .71). CONCLUSIONS: SRT boost is more effective in reverting the poor prognostic influence of local persistent disease.
Persistent Identifierhttp://hdl.handle.net/10722/220035
ISSN
2015 Impact Factor: 2.76
2015 SCImago Journal Rankings: 1.233

 

DC FieldValueLanguage
dc.contributor.authorYau, TK-
dc.contributor.authorSze, WM-
dc.contributor.authorLee, WMA-
dc.contributor.authorYeung, MW-
dc.contributor.authorLeung, KC-
dc.contributor.authorHung, WM-
dc.contributor.authorChan, WI-
dc.date.accessioned2015-10-16T06:16:35Z-
dc.date.available2015-10-16T06:16:35Z-
dc.date.issued2004-
dc.identifier.citationHead Neck, 2004, v. 26 n. 12, p. 1024-1030-
dc.identifier.issn1043-3074-
dc.identifier.urihttp://hdl.handle.net/10722/220035-
dc.description.abstractBACKGROUND: Nasopharyngeal carcinoma (NPC) with local persistence after primary radiotherapy carries a high risk of treatment failure. We compared the effectiveness of brachytherapy and a fractionated stereotactic radiotherapy (SRT) boost in improving tumor control. METHODS: We retrospectively reviewed the records of 755 patients with NPC treated from 1994 to 2001. Fifty-two patients (7%) had persistent local disease, but seven of them were unsuitable for radiotherapy boost. Overall, 24 patients received brachytherapy boost at a median dose of 20 Gy, and 21 patients received an SRT boost at a median dose of 15 Gy. RESULTS: Despite the radiotherapy boost, the overall 3-year local failure-free control rate was still significantly lower for patients with persistent disease than for the rest (71% vs 86%, p < .01). Only the SRT subgroup achieved a local failure-free control rate close to that of the complete responders (82% vs 86%, p = .71). CONCLUSIONS: SRT boost is more effective in reverting the poor prognostic influence of local persistent disease.-
dc.languageeng-
dc.relation.ispartofHead Neck-
dc.subjectAdolescent-
dc.subjectAdult-
dc.subjectAged-
dc.subjectAged, 80 and over-
dc.subjectBrachytherapy/*methods-
dc.subjectCarcinoma/mortality/pathology/radiotherapy-
dc.subjectCohort Studies-
dc.subjectCombined Modality Therapy-
dc.subjectDose Fractionation-
dc.subjectDose-Response Relationship, Radiation-
dc.subjectFemale-
dc.subjectFollow-Up Studies-
dc.subjectHumans-
dc.subjectImmunohistochemistry-
dc.subjectMale-
dc.subjectMiddle Aged-
dc.subjectNasopharyngeal Neoplasms/mortality/pathology/*radiotherapy-
dc.subjectNeoplasm Recurrence, Local/mortality/pathology/*radiotherapy/*surgery-
dc.subjectNeoplasm Staging-
dc.subjectRadiosurgery/*methods-
dc.subjectRadiotherapy Dosage-
dc.subjectRetrospective Studies-
dc.subjectRisk Assessment-
dc.subject*Salvage Therapy-
dc.subjectSurvival Analysis-
dc.subjectTreatment Outcome-
dc.titleEffectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma-
dc.typeArticle-
dc.identifier.emailLee, WMA: awmlee@hkucc.hku.hk-
dc.identifier.authorityLee, WMA=rp02056-
dc.identifier.doi10.1002/hed.20093-
dc.identifier.pmid15390194-
dc.identifier.hkuros266069-
dc.identifier.volume26-
dc.identifier.issue12-
dc.identifier.spage1024-
dc.identifier.epage1030-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats